Phase 1 dose escalation, food effect, and biomarker study of RG7388, a more potent second-generation MDM2 antagonist, in patients (pts) with solid tumors.
Lillian L. Siu
Research Funding - Roche
Antoine Italiano
No relevant relationships to disclose
Wilson H. Miller
Consultant or Advisory Role - Roche
Jean-Yves Blay
Honoraria - Roche
Research Funding - Roche
Jourik A. Gietema
Research Funding - Roche
Yung-Jue Bang
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
Linda R. Mileshkin
Consultant or Advisory Role - Roche Australia Ovarian Cancer Advisory Board (U)
Hal W. Hirte
No relevant relationships to disclose
Monica Reckner
Employment or Leadership Position - Roche TCRC
Stock Ownership - Roche
Brian Higgins
Employment or Leadership Position - Roche TCRC
Stock Ownership - Roche
Lori Jukofsky
Employment or Leadership Position - Roche TCRC
Stock Ownership - Roche
Steven Blotner
Employment or Leadership Position - Roche TCRC
Stock Ownership - Roche
Jianguo Zhi
Employment or Leadership Position - Roche TCRC
Stock Ownership - Roche TCRC
Steven Middleton
Employment or Leadership Position - Roche TCRC
Stock Ownership - Roche
Gwen L. Nichols
Employment or Leadership Position - Roche TCRC
Stock Ownership - Roche
Lin Chi Chen
Employment or Leadership Position - Roche TCRC
Stock Ownership - Roche